Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG known ✓ | P37231 | 6/20 | 0.43 |
| ▸ | HDAC11 known ✓ | Q96DB2 | 5/20 | 0.43 |
| ▸ | ESR1 known ✓ | P03372 | 1/20 | 0.43 |
| ▸ | PDE4A known ✓ | P27815 | 1/20 | 0.43 |
| ▸ | PDE3A known ✓ | Q14432 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 5/20 | 0.48 |
| ▸ | FAAH | O00519 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | CES2 | O00748 | 4/20 | 0.46 |
| ▸ | CES1 | P23141 | 4/20 | 0.46 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.44 |
| ▸ | HAO1 | Q9UJM8 | 1/20 | 0.44 |
| ▸ | PPARD | Q03181 | 6/20 | 0.43 |
| ▸ | PPARA | Q07869 | 6/20 | 0.43 |
| ▸ | GPR84 | Q9NQS5 | 5/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | TLR2 | O60603 | 2/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.43 |
| ▸ | FABP4 | P15090 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3634285 | 0.98 | KMT2A (0.52) | TSHRFAAHKMT2AMAPTCES2 | |
| SCHEMBL176299 | 0.98 | TSHR (0.50) | TSHRFAAHKMT2AMAPTCES2 | |
| SCHEMBL3131865 | 0.96 | KMT2A (0.54) | TSHRFAAHKMT2AMAPTCES2 | |
| SCHEMBL11795366 | 0.96 | KMT2A (0.54) | TSHRFAAHKMT2AMAPTCES2 | |
| Hydrogen Sulfide SCHEMBL9539728 | 0.96 | TSHR (0.48) | TSHRFAAHKMT2AMAPTCES2 | |
| SCHEMBL11796286 | 0.96 | KMT2A (0.54) | TSHRFAAHKMT2AMAPTCES2 | |
| SCHEMBL9295757 | 0.96 | KMT2A (0.54) | TSHRFAAHKMT2AMAPTCES2 | |
| SCHEMBL9539734 | 0.96 | TSHR (0.48) | TSHRFAAHKMT2AMAPTCES2 | |
| SCHEMBL3632919 | 0.96 | KMT2A (0.54) | TSHRFAAHKMT2AMAPTCES2 | |
| SCHEMBL29284351 | 0.94 | KMT2A (0.52) | TSHRFAAHKMT2AMAPTCES2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117986239-A | Irbesartan preparation method | 珠海润都制药股份有限公司 | 2024-05-07 | — | — | CN | claimed |
| EP-1853591-A1 | METHOD FOR OBTAINING A PHARMACEUTICALLY ACTIVE COMPOUND (IRBESARTAN) AND ITS SYNTHESIS INTERMEDIATE | INKE, S.A. (ES) | 2007-11-14 | — | — | EP | claimed |
| WO-2006089927-A1 | METHOD FOR OBTAINING A PHARMACEUTICALLY ACTIVE COMPOUND (IRBESARTAN) AND ITS SYNTHESIS INTERMEDIATE | INKE, S.A. (ES) | 2006-08-31 | — | — | WO | claimed |
| CN-117986239-A | Irbesartan preparation method | 珠海润都制药股份有限公司 | 2024-05-07 | — | — | CN | disclosed |
| CN-117836294-A | Biological antagonist containing aromatic ring, preparation method and application thereof | 上海翰森生物医药科技有限公司 | 2024-04-05 | — | — | CN | disclosed |
| CN-117085013-A | Biphenyl sulfonamide compounds useful for treating kidney diseases or conditions | 特拉维尔治疗公司 | 2023-11-21 | — | — | CN | disclosed |
| CN-117017985-A | Biphenyl sulfonamide compounds useful for treating kidney diseases or conditions | 特拉维尔治疗公司 | 2023-11-10 | — | — | CN | disclosed |
| CN-116983302-A | Biphenyl sulfonamide compounds useful for treating kidney diseases or conditions | 特拉维尔治疗公司 | 2023-11-03 | — | — | CN | disclosed |
| CN-114788823-A | Biphenyl sulfonamide compounds for use in the treatment of renal diseases or disorders | 特拉维尔治疗公司 | 2022-07-26 | — | — | CN | disclosed |
| CN-105001209-A | Synthetic method of irbesartan | CHEER FINE PHARMACEUTICAL ANHUI CO LTD | 2015-10-28 | — | — | CN | disclosed |
| US-7799928-B2 | Process for the preparation of irbesartan hydrochloride | CIPLA LIMITED (IN) | 2010-09-21 | — | — | US | disclosed |
| EP-0998463-B1 | PROCESS FOR THE PREPARATION OF 1,3-DIAZA-SPIRO (4.4) NON-1-EN-4-ONE DERIVATIVES AND 1-CYANO-1-ACYLAMINOCYCLOPENTANE INTERMEDIATES | SANOFI SYNTHELABO (FR) | 2003-04-02 | — | — | EP | disclosed |
| EP-0998462-B1 | PROCESS FOR THE PREPARATION OF 1,3-DIAZA-SPIRO (4.4) NON-1-EN-4-ONE DERIVATIVES AND 1-CYANO-1-ACYLAMINO-CYCLOPENTANE INTERMEDIATES | SANOFI SYNTHELABO (FR) | 2002-10-30 | — | — | EP | disclosed |
| US-6239286-B1 | REACTING 1-AMINO-1-CYANOCYCLOPENTANE WITH AN ACYL HALIDE; THEN AN ANHYDRIDE | SANOFI-SYNTHELABO (FR) | 2001-05-29 | — | — | US | disclosed |
| EP-0998463-A1 | PROCESS FOR THE PREPARATION OF 1,3-DIAZA-SPIRO (4.4) NON-1-EN-4-ONE DERIVATIVES AND 1-CYANO-1-ACYLAMINOCYCLOPENTANE INTERMEDIATES | SANOFI-SYNTHELABO (FR) | 2000-05-10 | — | — | EP | disclosed |
| EP-0998462-A1 | PROCESS FOR THE PREPARATION OF 1,3-DIAZA-SPIRO (4.4) NON-1-EN-4-ONE DERIVATIVES AND 1-CYANO-1-ACYLAMINO-CYCLOPENTANE INTERMEDIATES | SANOFI-SYNTHELABO (FR) | 2000-05-10 | — | — | EP | disclosed |
| EP-0998461-A1 | PROCESS FOR THE PREPARATION OF IMIDAZOLONES | SANOFI-SYNTHELABO (FR) | 2000-05-10 | — | — | EP | disclosed |
| WO-1999005120-A1 | PROCESS FOR THE PREPARATION OF 1,3-DIAZA-SPIRO (4.4) NON-1-EN-4-ONE DERIVATIVES AND 1-CYANO-1-ACYLAMINOCYCLOPENTANE INTERMEDIATES | SANOFI-SYNTHELABO (FR) | 1999-02-04 | — | — | WO | disclosed |
| WO-1999005119-A1 | PROCESS FOR THE PREPARATION OF 1,3-DIAZA-SPIRO (4.4) NON-1-EN-4-ONE DERIVATIVES AND 1-CYANO-1-ACYLAMINO-CYCLOPENTANE INTERMEDIATES | SANOFI-SYNTHELABO (FR) | 1999-02-04 | — | — | WO | disclosed |
| WO-1999005118-A1 | PROCESS FOR THE PREPARATION OF IMIDAZOLONES | SANOFI-SYNTHELABO (FR) | 1999-02-04 | — | — | WO | disclosed |